Glenmark Life Sciences Ltd Stock Analysis

BSE: 543322 | NSE: GLS | Pharmaceuticals & Drugs | Mid Cap

BSE Share Price 05-Dec-2022 18:01
436.05 3.35 (0.77%)

DeciZen - Make an Informed Decision on Glenmark Life Scienc

Overall Rating

1. Quality

2. Valuation

Fair

3. Price Trend

Glenmark Life Scienc Price Chart

P/E Ratio (SA) :
12.68
Market Cap :
5,301.8 Cr.
52-wk low :
375
52-wk high :
637.7
Bole Toh?

1. Is Glenmark Life Sciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Glenmark Life Sciences Ltd is a good quality company.

2. Is Glenmark Life Sciences Ltd undervalued or overvalued?

The key valuation ratios of Glenmark Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Glenmark Life Sciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Glenmark Life Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Glenmark Life Scienc:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Glenmark Life Sciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 0%0%0%0%0%31%463.8%134.6%72%30.9%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 000000.38861,5371,8852,1232,036
YoY Gr. Rt. %-NANANANANA3,54,468%73.4%22.6%12.6%-
Adj EPS 00000-7.918.628.432.933.834.1
YoY Gr. Rt. %-NANANANANANA52.5%15.8%2.7%-
BVPS (₹) 00000-25.48.237.369.8167.4174.9
Adj Net Profit 00000-0.4201306354414418
Cash Flow from Ops. 00000-0.510.4195388598-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA33.8%12.6%
Adj EPS NANA22%2.7%
BVPS 00173.6139.7
Share Price - - - -27.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 0000031462.912561.429.519.9
Op. Profit Mgn % 00000-5.228.730.831.629.128.4
Net Profit Mgn % 00000-17522.719.918.819.520.6
Debt to Equity 00000000000
Working Cap Days 000000193248258271333
Cash Conv. Cycle 000000123160151134245

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 33.80%

Net Profit is growing at healthy rate in last 3 years 21.96%

Return on Equity has declined versus last 3 years average to 19.90%

Sales growth is not so good in last 4 quarters at -0.38%

Latest Financials - Glenmark Life Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) 34.1 -
TTM Sales (₹ Cr.) 2,036 -
BVPS (₹.) 174.9 -
Reserves (₹ Cr.) 2,118 -
P/BV 2.47 -
PE 12.68 -
From the Market
52 Week Low / High (₹) 375.00 / 637.70
All Time Low / High (₹) 375.00 / 799.95
Market Cap (₹ Cr.) 5,302
Equity (₹ Cr.) 24.5
Face Value (₹) 2
Industry PE 37.8

Management X-Ray of Glenmark Life Scienc :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Glenmark Life Scienc

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Glenmark Life Sciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Glenmark Life Scienc on 05-Dec-2022 18:01 is : 436.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 05-Dec-2022 18:01 the market cap of Glenmark Life Scienc stood at ₹ 5,301.8.
The latest PE ratio of Glenmark Life Scienc as of 05-Dec-2022 18:01 is 12.68.
The latest PB ratio of Glenmark Life Scienc as of 05-Dec-2022 18:01 is 2.47
The 52-week high of Glenmark Life Scienc is ₹ 637.7 and the 52-week low is ₹ 375.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Glenmark Life Scienc is ₹ 2,036 ( Cr.) .

About Glenmark Life Sciences Ltd

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). It are also increasingly providing contract development and manufacturing operations (CDMO) services to a range of multinational and specialty pharmaceutical companies. It is a research and development (R&D)-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where there is growth potential in the future. Maintaining high standards of process innovation and quality in its R&D and manufacturing operations is critical to its brand and maintenance of long-term relationships with its customers.

The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India with an aggregate annual total installed capacity of 726.6 KL as of March 31, 2021. Its R&D laboratories focus on new product development and complex molecules, cost improvement programs, process improvements and oncology product development. To assist it with its R&D initiatives, it has established dedicated teams for new product development, complex products, oncology product development, technology transfer, life cycle management and project management.’ It has a professional and experienced management team. Its management team has demonstrated the ability to successfully build and integrate its businesses with various operating activities through their cumulative years of work experience. In particular, they have led the process through which it has created value through organic growth, built brand recognition and loyalty and identified new business opportunities.

Business area of the company

The company is in the business of making high-quality drugs by unlocking the possibilities of science.

Awards, accreditations and recognitions

  • 2015: Ankleshwar plant received ISO 14001:2015 certifying the management system of manufacturing  facility.
  • 2016: Dahej plant received ISO 14001:2015 certifying the management system of manufacturing facility.
  • 2016: Ankleshwar plant received BS OHSAS 18001:2017 certifying the management system of the manufacturing facility.
  • 2017: Ankleshwar plant was awarded Greentech Safety silver award by the Greentech Foundation for outstanding achievements in safety management.
  • 2018: Ankleshwar plant received ISO 14001:2015 re-certifying the management system of manufacturing facility.
  • 2018: Dahej plant received ISO 14001:2015 re-certifying the management system of manufacturing facility.
  • 2018: Ankleshwar plant was awarded Greentech Safety gold award by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Ankleshwar plant was awarded Greentech Safety Award as the winner in the pharmaceutical sector by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Dahej plant was awarded Greentech Safety Award for the year 2019 as the runner-up in the pharmaceutical sector by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Dahej plant was declared the winner of the Greentech Environment Award for the year 2019 for outstanding achievements in environment management in the pharmaceutical sector.
  • 2020: Dahej plant received ISO 45001:2018 certifying the management system of the manufacturing facility.
  • 2020: Dahej plant was declared the winner of the Greentech Environment Award for the year 2020 for outstanding achievements in environment protection.
  • 2021: Ankleshwar plant received ISO 45001:2018 certifying the management system of the manufacturing facility.
  • 2021: Ankleshwar plant received ISO 14001:2015 re-certifying the management system of the manufacturing facility.

Major events and milestones

  • 2001-2002: Established manufacturing plant at Kurkumbh, Maharashtra.
  • 2001-2002: The company’s Promoter established its API business.
  • 2004: Commenced manufacturing at Mohol, Maharashtra.
  • 2008: Ankleshwar plant at Gujarat inspected by US-FDA.
  • 2012: Ankleshwar plant inspected by PMDA and AFSSAPS.
  • 2013: Commenced manufacturing at Dahej, Gujarat.
  • 2013: Ankleshwar plant inspected by COFEPRIS.
  • 2015: Dahej plant inspected by US-FDA.
  • 2016: Dahej plant inspected by PMDA Japan.
  • 2018: Dahej plant inspected by EDQM, ANSM and US-FDA.
  • 2018: Mohol plant inspected by US-FDA.
  • 2019: The API business was spun off into Company.
  • 2019: Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan.
  • 2021: Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now